Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is positioned to potentially capitalize on a high-demand market with its innovative product candidate, roluperidone. With successful Phase 2a and 3 trials completed, an expected launch in 2029, and a unique mechanism of action compared to current treatments, the drug has the potential for significant sales and a valuation of $1.5B by 2034. The company also has the potential for future capital raises, further supporting the potential success of roluperidone in becoming a game-changing treatment for negative symptoms of schizophrenia.

Bears say

Minerva Neurosciences is currently developing a potential treatment for negative symptoms in schizophrenia, with the company recently initiating a confirmatory Phase 3 trial. However, there is a significant clinical risk that the candidate may fail to meet efficacy endpoints or produce safety/tolerability signals that impair approval and/or commercialization. Additionally, the company's previous Phase 3 trial for this candidate did not meet its primary endpoint, and while there were positive results in its Phase 2b trial, there is still uncertainty around the potential for positive results in the Phase 3 confirmatory trial.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.